Working… Menu

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04097821
Recruitment Status : Recruiting
First Posted : September 20, 2019
Last Update Posted : March 1, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 16, 2024
Estimated Study Completion Date : June 10, 2025